Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

NACompletedINTERVENTIONAL
Enrollment

840

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

December 17, 2020

Study Completion Date

July 1, 2021

Conditions
Acute Respiratory Distress SyndromeCritical Illness
Interventions
DRUG

Ulinastatin

200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.

OTHER

Usual care

Usual care in ICU.

Trial Locations (10)

100191

Peking University Third Hospital, Beijing

Unknown

Beijing Anzhen Hospital ,Capital Medical University, Beijing

Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing

Chinese Pla General Hospital, Beijing

Peking University Shenzhen Hospital, Shenzhen

The first affiliated hospital of Guangxi Medical University, Nanning

CANGZHOU People's Hospital, Cangzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

The second hospital of dalian medical university, Dalian

Central Hospital of Zi Bo, Zibo

All Listed Sponsors
collaborator

Chinese PLA General Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Central Hospital of Zi Bo

UNKNOWN

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

The Second Affiliated Hospital of Dalian Medical University

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Beijing Shijitan Hospital Affiliated to Capital Medical University

UNKNOWN

lead

Peking University Third Hospital

OTHER

NCT03089957 - Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS) | Biotech Hunter | Biotech Hunter